Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001255294-14-000095
Filing Date
2014-02-19
Accepted
2014-02-19 17:24:46
Documents
10
Period of Report
2013-12-31

Document Format Files

Seq Description Document Type Size
1 MAINBODY mainbody.htm 10-Q 282104
2 EX31_1 ex31_1.htm EX-31.1 9203
3 EX31_2 ex31_2.htm EX-31.2 9203
4 EX32_1 ex32_1.htm EX-32.1 4096
  Complete submission text file 0001255294-14-000095.txt   1525234

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE nepa-20131231.xml EX-101.INS 87947
6 XBRL SCHEMA FILE nepa-20131231.xsd EX-101.SCH 19418
7 XBRL CALCULATION FILE nepa-20131231_cal.xml EX-101.CAL 19512
8 XBRL DEFINITION FILE nepa-20131231_def.xml EX-101.DEF 40599
9 XBRL LABEL FILE nepa-20131231_lab.xml EX-101.LAB 93260
10 XBRL PRESENTATION FILE nepa-20131231_pre.xml EX-101.PRE 92734
Mailing Address 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS CA 90212
Business Address 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS CA 90212 (323) 424-3169
Rich Pharmaceuticals, Inc. (Filer) CIK: 0001504389 (see all company filings)

EIN.: 463259117 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54767 | Film No.: 14626852
SIC: 3430 Heating Equip, Except Elec & Warm Air; & Plumbing Fixtures